Clinical Trial

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2026 (before its estimated August 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2026-12-02 -> 2026-08-12 2026-08-06
minor Completion moved earlier: 2027-03-01 -> 2026-11-05 2026-08-06
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-26
Trial Details
NCT Number NCT07216482
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Hyperlipidemia
Enrollment 975 participants
Start Date 2025-11-11
Primary Completion 2026-08-12 (estimated)
Study Completion 2026-11-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-05